<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333603</url>
  </required_header>
  <id_info>
    <org_study_id>201601070MIND</org_study_id>
    <nct_id>NCT03333603</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenia Patients</brief_title>
  <official_title>Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetic and safety for the esomeprazole use for schizophrenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators prepare to recruit 30 schizophrenia patients in one year. Investigators will
      conduct a 8-week open label clinical trial for evaluation of the pharmacokinetic and safety
      of esomeprazole use for the schizophrenia. Investigators will give 40 mg/day esomeprazole in
      the first two weeks and 80 mg/day from the third week to the end of the trial. Investigators
      will check the area under the concentration of metabolites of esomeprazole on Day 1, Day 14
      and Day 56 and the genotype of CYP2C19. The GI symptoms and related drug side effects will be
      evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2016</start_date>
  <completion_date type="Actual">January 23, 2017</completion_date>
  <primary_completion_date type="Actual">January 23, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Investigators will give 40 mg/day esomeprazole in the first two weeks and 80 mg/day from the third week to the end of the trial. Investigators will check the area under the concentration of metabolites of esomeprazoleon Day 1, Day 14 and Day 56 and the genotype of CYP2C19. The GI symptoms and related drug side effects will be evaluated.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration analysis</measure>
    <time_frame>It will be assessed on Day 1 predose, Day 14 90 mins post dose, and Day 56 90 mins post dose</time_frame>
    <description>The pharmacokinetic parameters for esomeprazole and its main metabolites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CYP2C19 genotypes analysis</measure>
    <time_frame>The genotype will be assessed on Day 1</time_frame>
    <description>Investigators will genotype CYP2C19 genotype to determine that which metabolized type (poor metabolizer, intermediate metabolizer, and good metabolizer) of patients belong to.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>esomeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole</intervention_name>
    <description>esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56</description>
    <arm_group_label>esomeprazole</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. 20-65 years old

          2. Diagnosed as DSM-IV schizophrenia

          3. No adjustment of dose of major antipsychotics for at least 4 weeks

          4. Competence for inform consent

        Exclusion criteria

          1. Diagnosed with schizoaffective disorder or bipolar affective disorder or organic
             psychotic disorder

          2. Meet the diagnostic criteria of any substance abuse or dependence in the past 6 months

          3. History or evidence of any clinically significant medical or neurological disease,
             such as autoimmune disease, cancer, epilepsy, etc.

          4. Mental retardation or pervasive developmental disorders

          5. Past history of allergy to Esomeprazole

          6. patient who is taking clozapine„ÄÅ Depakin or Diazepam

          7. Pregnant

          8. The patient is under the order of involuntary admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Min Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Visiting Staff</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital Yunlin Branch</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

